Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

A Highly Potent Human sRAGE Protein for Treating Vascular Disease, Injury, or Inflammation

Posted Feb 22 2012 7:00pm

Description of Invention:
The receptor for advanced glycation end products (RAGE) is a cell surface protein that triggers signaling pathways leading to inflammation. RAGE-stimulated inflammation can contribute to adverse vascular conditions, such as atherosclerosis and restenosis. The soluble version of RAGE (sRAGE) binds the same target molecules (advanced glycation end products), but cannot activate inflammatory signaling pathways. For this reason, sRAGE is thought to act as a decoy for RAGE. sRAGE reduces inflammation and pathogenic consequences associated with RAGE signaling. The administration of sRAGE has been used to treat atherosclerosis and arterial restenosis in animal models. The inventors established a way to produce human sRAGE with more than 1000-fold greater potency than current methods. Production of full length human sRAGE in cultured mammalian cells enables addition of mammalian post-translational modifications that dramatically enhance potency. This invention covers methods of production, the resulting modified sRAGE molecules, and methods of using this highly potent sRAGE for treating adverse vascular conditions.

Applications:
  • Atherosclerosis therapeutics
  • Prevention of vascular inflammation
  • Treating vascular injuries due to angioplasty or traumatic injury
  • Treating vascular complications of Diabetes mellitus
  • Alzheimer’s Disease treatment based on amyloid-beta protein binding


Advantages:
  • Greater than 1000-fold increased potency over sRAGE produced in insect cells
  • Readily scalable production as a recombinant protein secreted from CHO cells
  • Simple affinity purification method


Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:
Li Lin (NIA)
Rui-ping Xiao (NIA)
Wen Wei (NIA)
Sungha Park (NIA)
Mark I Talan (NIA)


Patent Status:
HHS, Reference No. E-165-2011/0
US, Application No. 61/582,574 filed 03 Jan 2012


Related Technologies:
US, Application No. 12/652,395 filed 05 Jan 2010, Reference No. E-016-2009/0
US, Application No. 61/142,531 filed 05 Jan 2009, Reference No. E-016-2009/0


Relevant Publication:
  1. Lin L, et al. [ PMID 19273137 ]


Collaborative Research Opportunity:
The National Institute on Aging, Laboratory of Cardiovascular Science, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize sRAGE. For collaboration opportunities, please contact Vio Conley, M.S. at conleyv@mail.nih.gov .


For Licensing Information Please Contact:
Betty Tong Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tongb@mail.nih.gov
Phone: 301-594-6565
Fax: 301-402-0220


Ref No: 2380

Updated: 02/2012

Post a comment
Write a comment:

Related Searches